{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:15:55Z","timestamp":1761174955213,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ijid.2021.04.051","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T01:15:07Z","timestamp":1618794907000},"page":"69-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosis"],"prefix":"10.1016","volume":"107","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard R.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"S3","key":"10.1016\/j.ijid.2021.04.051_bib0005","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/ppul.24139","article-title":"Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis","volume":"53","author":"Akil","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.ijid.2021.04.051_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/jpp.JPP_2_17","article-title":"Dalbavancin use for the treatment of methicillin-resistant Staphylococcus aureus pneumonia","volume":"8","author":"Barber","year":"2017","journal-title":"J Pharmacol Pharmacother"},{"year":"2020","series-title":"Performance standards for antimcirobial susceptibility testing: 30th informational supplement","author":"CLSI. M100Ed30","key":"10.1016\/j.ijid.2021.04.051_bib0015"},{"issue":"2","key":"10.1016\/j.ijid.2021.04.051_bib0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2004.03.008","article-title":"Early intervention and prevention of lung disease in cystic fibrosis: a European consensus","volume":"3","author":"Doring","year":"2004","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijid.2021.04.051_bib0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fphar.2019.00849","article-title":"Antimicrobial treatment of Staphylococcus aureus in patients with cystic fibrosis","volume":"10","author":"Esposito","year":"2019","journal-title":"Front Pharmacol"},{"issue":"Supplement 1","key":"10.1016\/j.ijid.2021.04.051_bib0030","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ofid\/ofy346","article-title":"Global surveillance of antimicrobial resistance: 20 years of experience with the SENTRY Program","volume":"6","author":"Fuhrmeister","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2021.04.051_bib0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-016-0666-0","article-title":"Single-dose dalbavancin: a review in acute bacterial skin and skin structure infections","volume":"77","author":"Garnock-Jones","year":"2017","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ijid.2021.04.051_bib0040","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/thoraxjnl-2016-208949","article-title":"Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial","volume":"72","author":"Muhlebach","year":"2017","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.ijid.2021.04.051_bib0045","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/jac\/dky235","article-title":"Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015\u201316","volume":"73","author":"Pfaller","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ijid.2021.04.051_bib0050","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijmm.2018.02.003","article-title":"Staphylococcus aureus in the airways of cystic fibrosis patients \u2014 a retrospective long-term study","volume":"308","author":"Schwerdt","year":"2018","journal-title":"Int J Med Microbiol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221003623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221003623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:56:44Z","timestamp":1761119804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221003623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":10,"alternative-id":["S1201971221003623"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.04.051","relation":{},"ISSN":["1201-9712"],"issn-type":[{"type":"print","value":"1201-9712"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.04.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}